Advancing
cannabinoid-based
and targeted therapies
for the treatment of
cancer
Pascal Biosciences is dedicated to improving the lives of patients suffering from life-threatening diseases such as glioblastoma and other intractable cancers. We are developing novel cannabinoid-based small molecules and targeted antibodies, focusing on cancers for which there are no adequate therapies.
PAS-403 for Glioblastoma
PAS-403 is a cannabinoid-based small molecule that utilizes a unique mechanism of action to kill cancer cells. Clinical trials are targeted to begin in 2021.
PAS-393 for Cancer
PAS-393 is a cannabinoid that makes cancers visible to the immune system.
Latest News
Pascal Biosciences Announces Continuing Discussions with SŌRSE Technology and Testing of Cannabinoids for COVID-19 Treatment
May 27, 2020
Read More